Ranbaxy, Biocon inked similar deals | business | Hindustan Times
Today in New Delhi, India
Apr 25, 2017-Tuesday
-°C
New Delhi
  • Humidity
    -
  • Wind
    -

Ranbaxy, Biocon inked similar deals

business Updated: May 16, 2011 21:07 IST
HT Correspondent

Ranbaxy had entered into a deal with US' Merck in 2008 for drug discovery and clinical development in anti-infective drugs.

Upfront payment was not disclosed. Biocon also signed a similar deal with Pfizer in 2010, which gave Pfizer exclusive rights to market Biocon's biosimilar versions of top-selling insulins. Pfizer paid Biocon $200 million upfront and up to $150 million for development.